Aurigene Pharmaceutical Services Ltd., a global contract research, development, and manufacturing services organization (CRDMO), and Vipergen ApS, a niche small-molecule drug discovery service provider specialized in DNA encoded library (DEL) technologies, have partnered to co-market and offer DEL screening technologies to global customers as a standalone service or as an integrated drug discovery service.
Dr Reddy`s arm rolls AI&ML assisted drug discovery platform Aurigene.AI
Aurigene Pharmaceutical Services Ltd. introduces Aurigene.AI™, an artificial intelligence (AI) and machine learning (ML) assisted drug discovery platform
Prestige Biologics enters into MoU with Aurigene Pharmaceutical Services Limited to explore collaboration in CDMO market
Aurigene Pharmaceutical Services Ltd will establish its state-of-the-art biomanufacturing facility at an investment of USD 40 million here, which will generate employment to more than 250 people. ??Aurigene Pharmaceutical Services is a city-based leading contract research, development, and manufacturing organization (CRO/CDMO) and a long-term partner providing end-to-end solutions thereby accelerating innovation.
Aurigene Pharmaceutical Services, a unit of Indian drugmaker Dr. Reddy’s Laboratories, is planning to spend (PDF) $40 million to build a production facility for therapeutic proteins, antibodies and viral vectors.
Aurigene Pharmaceutical Services to expand biologics CDMO capacity with a new biomanufacturing facility
Dr. Reddy`s subsidiary hits the pause button on drug development for psoriasis
Dr. Reddy’s to explore opportunities for developing new drugs for NTDs
Dr Reddy's Laboratories on Thursday said its subsidiary has inked a pact with US-based Olema Pharmaceuticals Inc to research, develop and commercialise novel small molecule inhibitors of an undisclosed oncology target. Olema and Aurigene Discovery Technologies, a wholly-owned unit of Dr Reddy's Laboratories, have inked an exclusive global licence agreement in this regard.